Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
103 hedge funds and large institutions have $105M invested in Five Prime Therapeutics, Inc. in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 44 increasing their positions, 23 reducing their positions, and 24 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 23
10% less funds holding
Funds holding: 114 → 103 (-11)
37% less capital invested
Capital invested by funds: $167M → $105M (-$62.3M)
46% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 24
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $500K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.18M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.37M |
| 3 |
Renaissance Technologies
New York
|
+$1.02M |
| 4 |
Man Group
London,
United Kingdom
|
+$968K |
| 5 |
Squarepoint
New York
|
+$952K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.27M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.69M |
| 4 |
Axa
Paris,
France
|
-$1.33M |
| 5 |
Goldman Sachs
New York
|
-$906K |
FPRX Hedge Fund Activity: Q3 2019 in Review
103 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2019, worth a combined $105M — down 37% from $167M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of FPRX and 13 opened new positions — a net loss of 11 holders — while 23 trimmed existing stakes and 44 added.
The largest buyer was BVF Inc, adding an estimated $4.18M. The largest seller was Fidelity Investments, cutting an estimated $8.27M.
- 103 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2019, down from 114 in Q2 2019.
- Funds reported $105M of Five Prime Therapeutics, Inc. stock for Q3 2019, down 37% quarter-over-quarter.
- 13 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2019 and 24 closed out, a net change of -11 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q3 2019 was BVF Inc, an estimated $4.18M added.
- The largest Five Prime Therapeutics, Inc. seller in Q3 2019 was Fidelity Investments, an estimated $8.27M sold.
Based on aggregated 13F filings for Q3 2019.